TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 20084314

Group type: EXPERIMENTAL
Intervention: Circuit weight training (CWT)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Jogging (JOGG)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Both CWT and JOGG
Number of subjects: 50
Study: 17393617

Group type: EXPERIMENTAL
Intervention: Acupuncture combined with drugs (treatment group)
Number of subjects: 65

Group type: COMPARATOR
Intervention: Drugs only (control group)
Number of subjects: 65
Study: 15514511

Group type: EXPERIMENTAL
Intervention: 6-week hamstring-stretching program (5 days/week, 30 seconds hold, 3 repetitions)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Control group (no stretching)
Number of subjects: 43
Study: 11472316

Group type: EXPERIMENTAL
Intervention: Fructo oligosaccharides (10 g daily)
Number of subjects: 244

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 244

Group type: EXPERIMENTAL
Intervention: Fructo oligosaccharides
Number of subjects: 244
Study: 9935261

Group type: EXPERIMENTAL
Intervention: Intravenous alatrofloxacin (200 or 300 mg/day) followed by oral trovafloxacin (200 mg/day)
Number of subjects: 1701

Group type: EXPERIMENTAL
Intervention: Single-dose intravenous or oral prophylaxis with alatrofloxacin or trovafloxacin
Number of subjects: 1701

Group type: COMPARATOR
Intervention: Trovafloxacin
Number of subjects: 1701
Study: 8186345

Group type: EXPERIMENTAL
Intervention: Oral mesalazine (5-aminosalicylic acid) 2.4 g/day
Number of subjects: 110

Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 110
Study: 3364822

Group type: EXPERIMENTAL
Intervention: Methoxamine 10 mg
Number of subjects: 80

Group type: COMPARATOR
Intervention: Epinephrine 1 mg
Number of subjects: 80
Study: 554446

Group type: EXPERIMENTAL
Intervention: Haloperidol (10 to 60 mg daily)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Thioridazine (100 to 600 mg daily)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Drug holidays
Number of subjects: 30
Study: 29907076

Group type: EXPERIMENTAL
Intervention: Video intervention (Plan A)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Safe in the City (SITC) video
Number of subjects: 49
Study: 27790821

Group type: EXPERIMENTAL
Intervention: Guided Surgery
Number of subjects: 26

Group type: COMPARATOR
Intervention: Conventional Surgery
Number of subjects: 26
Study: 26262996

Group type: EXPERIMENTAL
Intervention: Sublingual GSH
Number of subjects: 20

Group type: COMPARATOR
Intervention: Oral GSH
Number of subjects: 20

Group type: COMPARATOR
Intervention: N-acetylcysteine (NAC)
Number of subjects: 20
Study: 23333293

Group type: EXPERIMENTAL
Intervention: DSM-IV-AUD symptoms (AUDS)
Number of subjects: 2039

Group type: EXPERIMENTAL
Intervention: AUDS report
Number of subjects: 2039

Group type: EXPERIMENTAL
Intervention: AUDS stability
Number of subjects: 2039

Group type: EXPERIMENTAL
Intervention: Overall pattern of AUDS
Number of subjects: 2039

Group type: EXPERIMENTAL
Intervention: AUDS in this age group
Number of subjects: 2039
Study: 21536207

Group type: EXPERIMENTAL
Intervention: MP+FM (miniplates + facemask)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: FM (facemask)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 45
Study: 18818130

Group type: EXPERIMENTAL
Intervention: Immunotherapy with cytokine-induced killer cells for 3 courses (CIK-I group)
Number of subjects: 127

Group type: EXPERIMENTAL
Intervention: Immunotherapy with cytokine-induced killer cells for 6 courses (CIK-II group)
Number of subjects: 127

Group type: COMPARATOR
Intervention: Control group (no postoperative adjuvant therapy)
Number of subjects: 127

Group type: EXPERIMENTAL
Intervention: Overall survival among the three groups
Number of subjects: 127
Study: 17334301

Group type: EXPERIMENTAL
Intervention: Coblation-assisted adenotonsillectomy (CAA)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Cold dissection adenotonsillectomy (CDA)
Number of subjects: 46
Study: 15121376

Group type: EXPERIMENTAL
Intervention: Pre-enucleation radiation
Number of subjects: 2290

Group type: EXPERIMENTAL
Intervention: I(125) brachytherapy
Number of subjects: 2290

Group type: COMPARATOR
Intervention: Both treatments
Number of subjects: 2290
Study: 11461949

Group type: COMPARATOR
Intervention: Conventional-dose CsA (target trough level 300 ng/ml)
Number of subjects: 313

Group type: EXPERIMENTAL
Intervention: Low-dose CsA (target trough level 150 ng/ml)
Number of subjects: 313

Group type: COMPARATOR
Intervention: Conventional-dose CsA
Number of subjects: 313

Group type: EXPERIMENTAL
Intervention: Low-dose CsA
Number of subjects: 313
Study: 9916865

Group type: EXPERIMENTAL
Intervention: Heat exposure test
Number of subjects: 10

Group type: COMPARATOR
Intervention: Insulin-tolerance test (ITT)
Number of subjects: 10
Study: 7924881

Group type: EXPERIMENTAL
Intervention: Memory based blood glucometer (ROMEO, Diva Medical Systems) used by group III (8 patients who bought the system)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Memory based blood glucometer (ROMEO, Diva Medical Systems) used by group I (8 patients who returned the system within one month)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Memory based blood glucometer (ROMEO, Diva Medical Systems) used by group II (8 patients who used the system as a loan)
Number of subjects: 24
Study: 2855478

Group type: EXPERIMENTAL
Intervention: Saline infusion (2 litres, 0.9% NaCl) over 60 min
Number of subjects: 7

Group type: COMPARATOR
Intervention: Control (no saline infusion)
Number of subjects: 7
Study: 30653692

Group type: EXPERIMENTAL
Intervention: Training in the Comprehensive Approach to Rehabilitation (CARe) methodology
Number of subjects: 14

Group type: COMPARATOR
Intervention: Control teams
Number of subjects: 14
Study: 28219329

Group type: EXPERIMENTAL
Intervention: Isolated ultrafiltration (1 hour after 4 hours of HD)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Hemodialysis with ultrafiltration
Number of subjects: 9

Group type: COMPARATOR
Intervention: Blood-volume-monitoring based ultrafiltration
Number of subjects: 9
Study: 25577189

Group type: EXPERIMENTAL
Intervention: Dissonance‐based Counter Attitudinal Therapy group treatment
Number of subjects: 72

Group type: COMPARATOR
Intervention: Usual care control condition
Number of subjects: 72
Study: 23727190

Group type: EXPERIMENTAL
Intervention: Add-on pregabalin at a dosage of 600 mg/day
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 21227624

Group type: EXPERIMENTAL
Intervention: Aspirin (ASA) therapy
Number of subjects: 80

Group type: COMPARATOR
Intervention: AA aggregation and PFA‐100 Epi
Number of subjects: 80

Group type: COMPARATOR
Intervention: AA aggregation and ADP aggregation
Number of subjects: 80

Group type: COMPARATOR
Intervention: ADP aggregation and PFA‐100 Epi
Number of subjects: 80
Study: 18506053

Group type: EXPERIMENTAL
Intervention: Preoperative statin therapy
Number of subjects: 31725
Study: 17255839

Group type: EXPERIMENTAL
Intervention: Lactoferrin-enhanced formula (850 mg/L)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Regular formula (102 mg/L)
Number of subjects: 52
Study: 15284262

Group type: EXPERIMENTAL
Intervention: C+P (cisplatin 50 mg/m2 plus paclitaxel 135 mg/m2)
Number of subjects: 264

Group type: COMPARATOR
Intervention: Cisplatin (50 mg/m2)
Number of subjects: 264
Study: 11401078

Group type: EXPERIMENTAL
Intervention: Positron emission tomography with 18F-fluoro-2-deoxy-D-glucose (FDG-PET)
Number of subjects: 0
Study: 9597213

Group type: EXPERIMENTAL
Intervention: 37.5 mg ephedrine i.m.
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 8180055

Group type: EXPERIMENTAL
Intervention: Nasal catheter
Number of subjects: 40

Group type: COMPARATOR
Intervention: Medium concentration facemask
Number of subjects: 40
Study: 3595698

Group type: EXPERIMENTAL
Intervention: Midazolam 15 mg
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Nitrazepam 5 mg
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 29697274

Group type: EXPERIMENTAL
Intervention: Eicosapentaenoic Acid (EPA) 2 g/day
Number of subjects: 64

Group type: COMPARATOR
Intervention: Standard polymeric diet (Control)
Number of subjects: 64
Study: 28279495

Group type: EXPERIMENTAL
Intervention: Intensive Short-Term Dynamic Psychotherapy (ISTDP)
Number of subjects: 341

Group type: COMPARATOR
Intervention: Cognitive-Behavioral Therapy (CBT)
Number of subjects: 341
Study: 26197768

Group type: EXPERIMENTAL
Intervention: Sequential chemoradiotherapy
Number of subjects: 254

Group type: COMPARATOR
Intervention: Chemotherapy or radiotherapy alone
Number of subjects: 254
Study: 22222177

Group type: EXPERIMENTAL
Intervention: Exercise group (3 exercises at proximal, medium, and distal segments of the lower limbs)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Placebo group (sham treatment with disconnected ultrasound equipment)
Number of subjects: 68
Study: 21439960

Group type: EXPERIMENTAL
Intervention: High-dose pegylated IFN-α2a (360 μg once per week or 180 μg twice per week) with ribavirin (1.0-1.2 or 1.2-1.6 g/d) for up to 72 weeks
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: High-dose pegylated IFN-α with ribavirin
Number of subjects: 83
Study: 18505948

Group type: EXPERIMENTAL
Intervention: Escitalopram
Number of subjects: 176

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 176

Group type: EXPERIMENTAL
Intervention: Problem-solving therapy
Number of subjects: 176

Group type: EXPERIMENTAL
Intervention: Escitalopram (intention-to-treat analysis)
Number of subjects: 176

Group type: EXPERIMENTAL
Intervention: Problem-solving therapy (intention-to-treat analysis)
Number of subjects: 176
Study: 16927381

Group type: EXPERIMENTAL
Intervention: Exposure-based behavioral treatment
Number of subjects: 82

Group type: COMPARATOR
Intervention: Non-exposure-based behavioral treatment
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Cognitive behavior therapy (core treatment)
Number of subjects: 82
Study: 12689783

Group type: EXPERIMENTAL
Intervention: Hemiparetic stroke patients
Number of subjects: 15

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 15
Study: 11218551

Group type: EXPERIMENTAL
Intervention: Coping styles (behavioural and emotional disengagement)
Number of subjects: 147

Group type: EXPERIMENTAL
Intervention: Attachment styles (less secure and more anxious)
Number of subjects: 147

Group type: EXPERIMENTAL
Intervention: Income level
Number of subjects: 147
Study: 8808422

Group type: EXPERIMENTAL
Intervention: Ranitidine 200 mg/day by continuous infusion
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Ranitidine 400 mg/day by continuous infusion
Number of subjects: 11
Study: 1400937

Group type: EXPERIMENTAL
Intervention: Swim-across technique with medium supplemented with 20% follicular fluid
Number of subjects: 124

Group type: COMPARATOR
Intervention: Swim-up technique (control)
Number of subjects: 124
Study: 3859981

Group type: EXPERIMENTAL
Intervention: Verbal information (INFO)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Demonstration (DEMO)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 150
Study: 31077790

Group type: EXPERIMENTAL
Intervention: Intensive telephone‐based smoking cessation counseling intervention incorporating lung cancer screening results
Number of subjects: 345

Group type: COMPARATOR
Intervention: Usual care (information pamphlet)
Number of subjects: 345
Study: 30268713

Group type: EXPERIMENTAL
Intervention: Age-appropriate preparation for children undergoing radiotherapy
Number of subjects: 63

Group type: COMPARATOR
Intervention: General anesthesia (regardless of group)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Traditional care
Number of subjects: 63
Study: 26621361

Group type: EXPERIMENTAL
Intervention: IFNgamma (human recombinant interferon 1 b gamma, trade name IMUKIN) administered in 3 subcutaneous escalating doses (100, 150 and 200 mug) over 4 weeks
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: IFNgamma (human recombinant interferon 1 b gamma, trade name IMUKIN)
Number of subjects: 9
Study: 25350474

Group type: EXPERIMENTAL
Intervention: Opioid treatment with an average of 144.5 ± 127.8 mg/d of MED, including 57.1% long-acting and 91.4% short-acting opioids.
Number of subjects: 35

Group type: COMPARATOR
Intervention: Positive urine drug tests (UDT) for illicit drugs or unprescribed medications (N = 15).
Number of subjects: 35
Study: 23242399

Group type: EXPERIMENTAL
Intervention: 8-week exercise intervention
Number of subjects: 60

Group type: COMPARATOR
Intervention: usual care (control group)
Number of subjects: 60
Study: 21029891

Group type: EXPERIMENTAL
Intervention: Phacoemulsification
Number of subjects: 199

Group type: COMPARATOR
Intervention: Manual SICS
Number of subjects: 199
Study: 18936571

Group type: EXPERIMENTAL
Intervention: Postoperative glucose (POG) levels
Number of subjects: 995

Group type: EXPERIMENTAL
Intervention: American Society of Anesthesia Classification (ASAC)
Number of subjects: 995

Group type: EXPERIMENTAL
Intervention: Emergency status
Number of subjects: 995

Group type: EXPERIMENTAL
Intervention: Postoperative glucose levels between 110 to 200 mg/dL
Number of subjects: 995

Group type: EXPERIMENTAL
Intervention: Postoperative glucose levels greater than 200 mg/dL
Number of subjects: 995
Study: 15890138

Group type: EXPERIMENTAL
Intervention: Stroke unit
Number of subjects: 457

Group type: COMPARATOR
Intervention: Stroke team
Number of subjects: 457

Group type: COMPARATOR
Intervention: Domiciliary care
Number of subjects: 457

Group type: COMPARATOR
Intervention: General wards (with stroke team support)
Number of subjects: 457
Study: 12181183

Group type: EXPERIMENTAL
Intervention: Barostat bag
Number of subjects: 8
Study: 10513787

Group type: EXPERIMENTAL
Intervention: Atenolol
Number of subjects: 10

Group type: COMPARATOR
Intervention: Amlodipine
Number of subjects: 10

Group type: COMPARATOR
Intervention: Isosorbide-5-mononitrate
Number of subjects: 10
Study: 8557016

Group type: EXPERIMENTAL
Intervention: Hypothermia (30.4 ± 0.8 degrees C)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Normothermic control group
Number of subjects: 19
Study: 1936476

Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Glibenclamide
Number of subjects: 35

Group type: COMPARATOR
Intervention: Metformin and Glibenclamide
Number of subjects: 35

Group type: COMPARATOR
Intervention: Metformin (long term therapy)
Number of subjects: 35
Study: 6757983

Group type: EXPERIMENTAL
Intervention: Femoxetine
Number of subjects: 77

Group type: COMPARATOR
Intervention: Amitriptyline
Number of subjects: 77
Study: 31472044

Group type: EXPERIMENTAL
Intervention: Phosphate solubilizing + salt-tolerant bacteria at 4 dS/m salinity level
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Siderophore producing + salt-tolerant bacteria at 8 dS/m
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Phosphate solubilizing + salt-tolerant bacteria at 8 dS/m
Number of subjects: 2
Study: 29179559

Group type: EXPERIMENTAL
Intervention: Aerobic exercise program (3 days/week, 55-60 min/session from gestational Weeks 9-11 until Weeks 38-39)
Number of subjects: 65

Group type: COMPARATOR
Intervention: Standard care (control group)
Number of subjects: 65
Study: 27503042

Group type: EXPERIMENTAL
Intervention: Bilastine 20 mg
Number of subjects: 24

Group type: COMPARATOR
Intervention: Hydroxyzine 50 mg (active control)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 25204467

Group type: EXPERIMENTAL
Intervention: Single-sided questionnaire
Number of subjects: 4600

Group type: EXPERIMENTAL
Intervention: Internet option
Number of subjects: 4600

Group type: EXPERIMENTAL
Intervention: Single-sided questionnaire + Internet option
Number of subjects: 4600

Group type: COMPARATOR
Intervention: No intervention (reference group)
Number of subjects: 4600
Study: 23259498

Group type: EXPERIMENTAL
Intervention: Health-Social Transitional Care Management Program (HSTCMP)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study: 19699071

Group type: EXPERIMENTAL
Intervention: Nutraceutical combination (NC) - 500 mg berberine, 200 mg red yeast rice, 10 mg policosanols
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 18201459

Group type: EXPERIMENTAL
Intervention: Nasal passive humidifiers (NPHs) applied in both nostrils for 1 hour on the 2nd postoperative day
Number of subjects: 40
Study: 15738285

Group type: EXPERIMENTAL
Intervention: Microbiopsy
Number of subjects: 21

Group type: COMPARATOR
Intervention: Bergström biopsy
Number of subjects: 21
Study: 12088774

Group type: EXPERIMENTAL
Intervention: HRV (SDNN <65.3 ms)
Number of subjects: 127

Group type: EXPERIMENTAL
Intervention: Increase in SDNN
Number of subjects: 127
Study: 10201103

Group type: EXPERIMENTAL
Intervention: Prompting to manipulate leisure items
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Reinforcing object manipulation
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Blocking SIB while reinforcing manipulation
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Preventing SIB with protective equipment while reinforcing object manipulation
Number of subjects: 2
Study: 7794069

Group type: EXPERIMENTAL
Intervention: 0.2 mg/kg/day recombinant human growth hormone (rhGH)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 2218422

Group type: EXPERIMENTAL
Intervention: Ofloxacin 200 mg b.i.d.
Number of subjects: 84

Group type: COMPARATOR
Intervention: Pivmecillinam 700 mg t.i.d.
Number of subjects: 84
Study: 334225

Group type: EXPERIMENTAL
Intervention: Nomifensine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 28810477

Group type: EXPERIMENTAL
Intervention: Acceptance and commitment therapy self-help intervention (self-help booklet and telephone support)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 0
Study: 31046819

Group type: EXPERIMENTAL
Intervention: Fe‐fortified lentils
Number of subjects: 1260

Group type: COMPARATOR
Intervention: Unfortified lentils
Number of subjects: 1260

Group type: COMPARATOR
Intervention: Usual intake
Number of subjects: 1260
Study: 29103664

Group type: EXPERIMENTAL
Intervention: Canagliflozin 100 mg
Number of subjects: 215

Group type: EXPERIMENTAL
Intervention: Canagliflozin 300 mg
Number of subjects: 215

Group type: EXPERIMENTAL
Intervention: Canagliflozin 100 mg and 300 mg
Number of subjects: 215

Group type: EXPERIMENTAL
Intervention: Canagliflozin
Number of subjects: 215

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 215
Study: 25168676

Group type: EXPERIMENTAL
Intervention: Triple P-Positive Parenting Program
Number of subjects: 76

Group type: COMPARATOR
Intervention: Standard diabetes care
Number of subjects: 76
Study: 23783081

Group type: EXPERIMENTAL
Intervention: Quinvaxem(®) vaccine administered at 6, 10, and 14 weeks of age
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Quinvaxem(®) vaccine
Number of subjects: 0
Study: 21272273

Group type: EXPERIMENTAL
Intervention: Cognitive behaviour therapy
Number of subjects: 129

Group type: EXPERIMENTAL
Intervention: Skills training for symptom management
Number of subjects: 129

Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 129

Group type: EXPERIMENTAL
Intervention: Profile 1 (highest openness score)
Number of subjects: 129

Group type: EXPERIMENTAL
Intervention: Profile 3 (highest extraversion score)
Number of subjects: 129

Group type: EXPERIMENTAL
Intervention: Neuroticism
Number of subjects: 129
Study: 19057416

Group type: EXPERIMENTAL
Intervention: Herbal formula (equivalent to 3,150 mg dry herb)
Number of subjects: 93

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 93
Study: 16378147

Group type: EXPERIMENTAL
Intervention: Preoperative duplex scan before varicose vein surgery
Number of subjects: 293

Group type: COMPARATOR
Intervention: Control group (no preoperative duplex scan)
Number of subjects: 293

Group type: EXPERIMENTAL
Intervention: Both groups of VV patients
Number of subjects: 293
Study: 14615473

Group type: EXPERIMENTAL
Intervention: 10% oral solution of levetiracetam (750 mg)
Number of subjects: 24

Group type: COMPARATOR
Intervention: 750-mg tablet of levetiracetam
Number of subjects: 24
Study: 12789964

Group type: EXPERIMENTAL
Intervention: Minocycline microspheres plus scaling and root planing (SRP)
Number of subjects: 921

Group type: EXPERIMENTAL
Intervention: Minocycline microspheres plus SRP
Number of subjects: 921

Group type: COMPARATOR
Intervention: SRP plus vehicle (placebo)
Number of subjects: 921

Group type: COMPARATOR
Intervention: SRP alone
Number of subjects: 921

Group type: EXPERIMENTAL
Intervention: Minocycline microspheres
Number of subjects: 921
Study: 9589819

Group type: EXPERIMENTAL
Intervention: Mometasone furoate 0.1%-salicylic acid 5% ointment
Number of subjects: 408

Group type: COMPARATOR
Intervention: Mometasone furoate 0.1% ointment
Number of subjects: 408
Study: 8025983

Group type: EXPERIMENTAL
Intervention: Captopril (50 mg daily)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 58
Study: 2638464

Group type: EXPERIMENTAL
Intervention: Oradyne‐Z mouthwash
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo solution
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Chlorhexidine mouthwash
Number of subjects: 24
Study: 969820

Group type: EXPERIMENTAL
Intervention: Digitalis
Number of subjects: 2

Group type: COMPARATOR
Intervention: Isoproterenol, Propranolol, Verapamil, Calcium chloride
Number of subjects: 2
Study: 30773266

Group type: EXPERIMENTAL
Intervention: Liraglutide (aiming at 3 mg daily for 12 weeks)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Control period (5 weeks)
Number of subjects: 33
Study: 28103158

Group type: EXPERIMENTAL
Intervention: sumatriptan iontophoretic transdermal system (TDS)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: lasmiditan
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: PNU‐142633
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: NOX‐188
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 5‐HT1F receptor agonist lasmiditan
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 5‐HT2B and 5‐HT7 receptor antagonism
Number of subjects: 0
Study: 25371534

Group type: EXPERIMENTAL
Intervention: HZ/su vaccine (50 µg varicella-zoster virus glycoprotein E [gE] combined with AS01B adjuvant)
Number of subjects: 123

Group type: COMPARATOR
Intervention: Saline (placebo)
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: HZ/su vaccine
Number of subjects: 123
Study: 23547788

Group type: EXPERIMENTAL
Intervention: E. guineensis leaf extract 500 mg
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: E. guineensis leaf extract 1000 mg
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: F. deltoidea leaf extract 1000 mg
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control (no specific control group mentioned)
Number of subjects: 30